140 related articles for article (PubMed ID: 37487948)
1. Upregulation of Parkinson's disease-associated protein alpha-synuclein suppresses tumorigenesis via interaction with mGluR5 and gamma-synuclein in liver cancer.
Yang HM; Cheng YZ; Hou TZ; Fan JK; Gu L; Zhang JN; Zhang H
Arch Biochem Biophys; 2023 Aug; 744():109698. PubMed ID: 37487948
[TBL] [Abstract][Full Text] [Related]
2. Metabotropic glutamate receptor 5 inhibits α-synuclein-induced microglia inflammation to protect from neurotoxicity in Parkinson's disease.
Zhang YN; Fan JK; Gu L; Yang HM; Zhan SQ; Zhang H
J Neuroinflammation; 2021 Jan; 18(1):23. PubMed ID: 33461598
[TBL] [Abstract][Full Text] [Related]
3. The Parkinson's disease-associated protein α-synuclein inhibits hepatoma by exosome delivery.
Hou TZ; Yang HM; Cheng YZ; Gu L; Zhang JN; Zhang H
Mol Carcinog; 2023 Aug; 62(8):1163-1175. PubMed ID: 37144864
[TBL] [Abstract][Full Text] [Related]
4. Metabotropic glutamate receptor 5 mediates the suppressive effect of 6-OHDA-induced model of Parkinson's disease on liver cancer.
Xi SS; Bai XX; Gu L; Bao LH; Yang HM; An W; Wang XM; Zhang H
Pharmacol Res; 2017 Jul; 121():145-157. PubMed ID: 28455267
[TBL] [Abstract][Full Text] [Related]
5. PDZ Scaffold Protein CAL Couples with Metabotropic Glutamate Receptor 5 to Protect Against Cell Apoptosis and Is a Potential Target in the Treatment of Parkinson's Disease.
Luo WY; Xing SQ; Zhu P; Zhang CG; Yang HM; Van Halm-Lutterodt N; Gu L; Zhang H
Neurotherapeutics; 2019 Jul; 16(3):761-783. PubMed ID: 31073978
[TBL] [Abstract][Full Text] [Related]
6. Dynamic Changes in Striatal mGluR1 But Not mGluR5 during Pathological Progression of Parkinson's Disease in Human Alpha-Synuclein A53T Transgenic Rats: A Multi-PET Imaging Study.
Yamasaki T; Fujinaga M; Kawamura K; Furutsuka K; Nengaki N; Shimoda Y; Shiomi S; Takei M; Hashimoto H; Yui J; Wakizaka H; Hatori A; Xie L; Kumata K; Zhang MR
J Neurosci; 2016 Jan; 36(2):375-84. PubMed ID: 26758830
[TBL] [Abstract][Full Text] [Related]
7. Blockade of metabotropic glutamate receptor 5 protects against DNA damage in a rotenone-induced Parkinson's disease model.
Xia N; Zhang Q; Wang ST; Gu L; Yang HM; Liu L; Bakshi R; Yang H; Zhang H
Free Radic Biol Med; 2015 Dec; 89():567-80. PubMed ID: 26454081
[TBL] [Abstract][Full Text] [Related]
8. In vitro modulation of mTOR and mGlur5 influence α-synuclein accumulation.
Xing V; Biggar K; Ferguson SSG; Hayley S
Mol Brain; 2024 Feb; 17(1):9. PubMed ID: 38360671
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of metabotropic glutamate receptor 5 inhibits hepatoma development in a neurotoxin rotenone-induced Parkinson's disease model.
Bai XX; Gu L; Yang HM; Xi SS; Xia N; Zhang S; Zhang H
Toxicol Lett; 2018 May; 288():71-81. PubMed ID: 29458170
[TBL] [Abstract][Full Text] [Related]
10. Sigma-2 receptor antagonists rescue neuronal dysfunction induced by Parkinson's patient brain-derived α-synuclein.
Limegrover CS; Yurko R; Izzo NJ; LaBarbera KM; Rehak C; Look G; Rishton G; Safferstein H; Catalano SM
J Neurosci Res; 2021 Apr; 99(4):1161-1176. PubMed ID: 33480104
[TBL] [Abstract][Full Text] [Related]
11. Autophagy and Alpha-Synuclein: Relevance to Parkinson's Disease and Related Synucleopathies.
Xilouri M; Brekk OR; Stefanis L
Mov Disord; 2016 Feb; 31(2):178-92. PubMed ID: 26813776
[TBL] [Abstract][Full Text] [Related]
12. Alterations in mGluR5 expression and signaling in Lewy body disease and in transgenic models of alpha-synucleinopathy--implications for excitotoxicity.
Price DL; Rockenstein E; Ubhi K; Phung V; MacLean-Lewis N; Askay D; Cartier A; Spencer B; Patrick C; Desplats P; Ellisman MH; Masliah E
PLoS One; 2010 Nov; 5(11):e14020. PubMed ID: 21103359
[TBL] [Abstract][Full Text] [Related]
13. Hippocampal neuronal cells that accumulate α-synuclein fragments are more vulnerable to Aβ oligomer toxicity via mGluR5--implications for dementia with Lewy bodies.
Overk CR; Cartier A; Shaked G; Rockenstein E; Ubhi K; Spencer B; Price DL; Patrick C; Desplats P; Masliah E
Mol Neurodegener; 2014 May; 9():18. PubMed ID: 24885390
[TBL] [Abstract][Full Text] [Related]
14. Striatal changes underlie MPEP-mediated suppression of the acquisition and expression of pramipexole-induced place preference in an alpha-synuclein rat model of Parkinson's disease.
Loiodice S; McGhan P; Gryshkova V; Fleurance R; Dardou D; Hafidi A; Nogueira da Costa A; Durif F
J Psychopharmacol; 2017 Oct; 31(10):1323-1333. PubMed ID: 28631520
[TBL] [Abstract][Full Text] [Related]
15. A new perspective in Parkinson's disease, chaperone-mediated autophagy.
Li B; Zhang Y; Yuan Y; Chen N
Parkinsonism Relat Disord; 2011 May; 17(4):231-5. PubMed ID: 21215675
[TBL] [Abstract][Full Text] [Related]
16. Blockade of metabotropic glutamate receptor 5 attenuates axonal degeneration in 6-hydroxydopamine-induced model of Parkinson's disease.
Zhang JN; Huang YL; Yang HM; Wang Y; Gu L; Zhang H
Mol Cell Neurosci; 2021 Jan; 110():103572. PubMed ID: 33248235
[TBL] [Abstract][Full Text] [Related]
17. Autophagy modulates SNCA/α-synuclein release, thereby generating a hostile microenvironment.
Poehler AM; Xiang W; Spitzer P; May VE; Meixner H; Rockenstein E; Chutna O; Outeiro TF; Winkler J; Masliah E; Klucken J
Autophagy; 2014; 10(12):2171-92. PubMed ID: 25484190
[TBL] [Abstract][Full Text] [Related]
18. Piperine promotes autophagy flux by P2RX4 activation in
Li R; Lu Y; Zhang Q; Liu W; Yang R; Jiao J; Liu J; Gao G; Yang H
Autophagy; 2022 Mar; 18(3):559-575. PubMed ID: 34092198
[TBL] [Abstract][Full Text] [Related]
19. Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease.
Murphy KE; Gysbers AM; Abbott SK; Tayebi N; Kim WS; Sidransky E; Cooper A; Garner B; Halliday GM
Brain; 2014 Mar; 137(Pt 3):834-48. PubMed ID: 24477431
[TBL] [Abstract][Full Text] [Related]
20. alpha-synuclein degradation by autophagic pathways: a potential key to Parkinson's disease pathogenesis.
Xilouri M; Vogiatzi T; Vekrellis K; Stefanis L
Autophagy; 2008 Oct; 4(7):917-9. PubMed ID: 18708765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
